Bayer Granted Fast Track Approval from FDA for Cancer Drug

Bayer Pharmaceuticals announced this week that its cancer drug, Copanlisib, has been granted priority review by the FDA. The expedited process means that Bayer will know within 6 months whether Copanlisib has been granted regulatory approval versus the standard 10...